Cargando…

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

BACKGROUND: Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vickers, Andrew J, Sjoberg, Daniel D, Ulmert, David, Vertosick, Emily, Roobol, Monique J, Thompson, Ian, Heijnsdijk, Eveline AM, De Koning, Harry, Atoria-Swartz, Coral, Scardino, Peter T, Lilja, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922189/ https://www.ncbi.nlm.nih.gov/pubmed/24512643 http://dx.doi.org/10.1186/1741-7015-12-26

Ejemplares similares

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam
por: Wever, Elisabeth M., et al.
Publicado: (2010)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2010)

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2013)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

Interpreting Overdiagnosis Estimates in Population-based Mammography Screening
por: de Gelder, Rianne, et al.
Publicado: (2011)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
por: Ulmert, David, et al.
Publicado: (2008)

Cost‐effectiveness of multiparametric magnetic resonance imaging and MRI‐guided biopsy in a population‐based prostate cancer screening setting using a micro‐simulation model
por: Getaneh, Abraham M., et al.
Publicado: (2021)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project
por: Assel, Melissa J., et al.
Publicado: (2017)

Overdiagnosis and overtreatment of early detected prostate cancer
por: Bangma, C. H., et al.
Publicado: (2007)

Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean
por: Bae, Jong-Myon
Publicado: (2015)

An empirical study of race times in recreational endurance runners
por: Vickers, Andrew J., et al.
Publicado: (2016)

Active surveillance for prostate cancer
por: Shill, Daniela K., et al.
Publicado: (2021)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach
por: Pathirana, Thanya, et al.
Publicado: (2019)

Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer
por: Ferro, Matteo, et al.
Publicado: (2021)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
por: Vickers, Andrew J, et al.
Publicado: (2008)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Prostate cancer screening and active surveillance in the Western world
por: Roobol, Monique J.
Publicado: (2018)

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
por: Jegerlehner, Sabrina, et al.
Publicado: (2019)

Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview study
por: Nielsen, Sigrid Brisson, et al.
Publicado: (2020)

Personalized strategies in population screening for prostate cancer
por: Remmers, Sebastiaan, et al.
Publicado: (2020)

Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future?
por: Roobol, Monique J.
Publicado: (2021)

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening
por: van Luijt, P. A., et al.
Publicado: (2016)

Prostate cancer screening in Europe and Asia
por: Zhang, Kai, et al.
Publicado: (2017)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
por: Pashayan, N, et al.
Publicado: (2006)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Ethnicity and prostate cancer: the way to solve the screening problem?
por: Bokhorst, Leonard P., et al.
Publicado: (2015)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

From PROMIS to PRO-MRI in primary prostate cancer diagnosis
por: Schoots, Ivo G., et al.
Publicado: (2017)

Overdiagnosis and overtreatment of breast cancer: Is overdiagnosis an issue for radiologists?
por: Warren, Ruth, et al.
Publicado: (2006)

Nanocytological Field Carcinogenesis Detection to Mitigate Overdiagnosis of Prostate Cancer: A Proof of Concept Study
por: Roy, Hemant K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qku94f4dd8d9r73sjq7krbr4ui